Winway Health Desk
Biogen ramps up its SMA rivalry with Novartis with new Spinraza...
What do you do when a hot new gene therapy threatens to unseat your drug as the treatment of choice for a devastating disease?
For...
Gestational diabetes tests are carried out too late, researchers say
Current screening programmes for gestational diabetes are being carried out too late to adequately prevent health issues in mother and baby, researchers...
Simple eye scan could help detect undiagnosed type 2 diabetes
A pioneering eye scan has been developed which could help screen for undiagnosed type 2 diabetes in the future.The biomicroscope screening involves...
Merck, Eisai’s Keytruda-Lenvima combo wins simultaneous OKs in U.S., Canada and...
Talk about making pharma history. Merck & Co.’s Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with partner Eisai’s Lenvima.
Drug regulators...
FDA Approves Keytruda (pembrolizumab) plus Lenvima (lenvatinib) Combination Treatment for Patients...
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.-- September 17, 2019 -- (BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and...
Health systems best positioned to ‘eat’ medical inflation, Fairview CEO says
Fairview Health Services CEO James Hereford gives opening keynote at INVEST Digital Health in Minneapolis, Sept. 17, 2019
Growing healthcare costs are creating a crisis...
EASD: Lilly, BI tout new Jardiance kidney analysis as rival J&J...
BARCELONA—Eli Lilly and Boehringer Ingelheim, eager to keep pace with rivals, are out with new Jardiance kidney disease data in a patient population they...
FDA accepts application for Merck Ebola vaccine
The high-level isolation unit for Ebola patients at London’s Royal Free Hospital
The Food and Drug Administration has accepted and given priority review to an...
Novartis’ Cosentyx chases Eli Lilly’s Taltz with new spondyloarthritis data
Novartis’ Cosentyx is in a heated contest with Eli Lilly’s Taltz for IL-17A inhibitor supremacy, duking it out in three indications. Now, with new...
Lilly’s biomarker-driven drug shows strong, durable response rates in lung cancer...
More than two-thirds of patients with non-small cell lung cancer in a trial of a drug designed to treat cancers based on a genetic...
